Pfizer
Pfizer/Janssen Alzheimer’s drug dropped after failure
August 7, 2012Research and Development, Sales and Marketing Alzheimer's, Janssen, Pfizer, bapineuzumab
Pfizer and Janssen have decided to drop their investigational Alzheimer’s drug bapineuzumab after it failed a second late-stage study. The …
Pfizer Sandwich site sold to private consortium
August 3, 2012Business Services, Research and Development, Sales and Marketing Jobs, Pfizer, R&D, Sandwich, cuts
The Sandwich Discovery Park in Kent has found new owners, 18 months after Pfizer decided to pull out from the …
Shire posts strong quarter results
August 2, 2012Sales and Marketing ADHD, Adderall XR, Pfizer, Q2, Shire, results
Shire has posted a set of healthy financials for the second quarter, buoyed by its ADHD and rare drug portfolio. …
Pfizer’s RA pill impresses in Phase III
August 1, 2012Research and Development, Sales and Marketing FDA, JAK, Pfizer, RA
Pfizer’s investigational arthritis drug tofacitinib has beaten methotrexate in a head-to-head study. Tofacitinib, an oral Janus kinase (JAK) inhibitor, is …
Lipitor loss continues to hit Pfizer sales
July 31, 2012Sales and Marketing Enbrel, Lipitor, Pfizer, Prevnar, Q2
Pfizer has posted a loss in revenue for the second quarter as the firm continues to feel the impact of …
Prevenar 13 rejected for UK vaccination programme
July 27, 2012Sales and Marketing JCVI, Pfizer, Pneumovax, Sanofi Pasteur, prevenar 13
The UK’s joint committee on vaccination and immunisation is recommending against a switch to Pfizer’s pneumococcal vaccine Prevenar 13 from …
Pfizer and Janssen’s Alzheimer’s drug fails
July 24, 2012Research and Development, Sales and Marketing Alzheimer's, Janssen, Pfizer, bapineuzumab
Pfizer and Janssen’s investigational Alzheimer’s drug bapineuzumab is no better than placebo, according to a new study. The Phase III …
John LaMattina: FDA tries to disavow role in higher hurdles for new drugs
July 2, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, John LaMattina, Pfizer, US, discovery, drug
As evidenced by various blog posts that I have written over the past year (e.g., “Why Doesn’t the FDA Get …
Apps not the way forward for trial recruitment
June 28, 2012Medical Communications Pfizer, apps, digital, virtual trial
After Pfizer admitted defeat in the first ever ‘virtual trial’ earlier this year, it seems that we are not yet …
FDA delays Eliquis approval
June 26, 2012Sales and Marketing BMS, Eliquis, FDA, Pfizer, Xarelto
The FDA has asked Pfizer and Bristol-Myers Squibb for more information about its key blood thinner Eliquis. The US regulator …
MPs find NHS bodies still blocking treatments
June 25, 2012Sales and Marketing CCGs, MPs, NHS, NICE, PCTs, Pfizer, viagra
The Labour party has uncovered new restrictions to treatments and drugs in the NHS, which it says is hurting patients …
Pfizer Gaucher drug rejected by CHMP
June 25, 2012Sales and Marketing Elelyso, FDA, Gaucher, Pfizer, Shire, Vpriv
A European committee has refused marketing authorisation for Pfizer’s Gaucher disease drug Elelyso, as a competitor drug has exclusivity to …
Pfizer vows to learn from virtual trial failure
June 22, 2012Medical Communications Pfizer, REMOTE, Think science now, digital
Several months after Pfizer failed to recruit patients to its first ever virtual trial, the firm said it was looking …
FDA holds up Pfizer’s rare disease drug tafamidis
June 19, 2012Research and Development, Sales and Marketing FDA, Pfizer, rare disease, tafamidis
The FDA has sent Pfizer a Complete Response Letter about its rare disease drug tafamidis meglumine. The US regulator is …
Pfizer launches ‘Campaign Against Migraine’ website
June 18, 2012Medical Communications Botox, Pfizer, Relpax, digital, migraine
Pfizer has launched a new website called ‘Campaign Against Migraine’ to help migraine sufferers in the US learn more about …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
